Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

被引：48

作者：

Bachanova, Veronika ^{[1
]}

Ghobadi, Armin ^{[2
]}

Patel, Krish ^{[3
]}

Park, Jae H. ^{[4
]}

Flinn, Ian W. ^{[5
]}

Shah, Prutha ^{[6
]}

Wong, Carol ^{[6
]}

Bickers, Cara ^{[6
]}

Szabo, Peter ^{[6
]}

Wong, Lilly ^{[6
]}

Valamehr, Bahram ^{[6
]}

Atwal, Siminder ^{[6
]}

Chu, Yu-Waye ^{[6
]}

Elstrom, Rebecca ^{[6
]}

Strati, Paolo ^{[7
]}

机构：

[1] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN USA

[2] Washington Univ, Sch Med, St Louis, MO USA

[3] Swedish Canc Inst, Seattle, WA USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Fate Therapeut Inc, San Diego, CA USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

关键词：

D O I：

10.1182/blood-2021-151185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

823

引用

页数：6